BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vittal A, Ghany MG. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. Clin Liver Dis. 2019;23:417-432. [PMID: 31266617 DOI: 10.1016/j.cld.2019.04.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Wu X, Ye Y, Ye L, Han S, Wang X, Yu H. Liver Histology of Treatment-Naïve Children with Chronic Hepatitis B Virus Infection in Shanghai China. Int J Infect Dis 2022:S1201-9712(22)00487-8. [PMID: 36028208 DOI: 10.1016/j.ijid.2022.08.017] [Reference Citation Analysis]
2 Ahmed Z, Shetty A, Victor DW, Kodali S. Viral hepatitis: A narrative review of hepatitis A–E. World J Meta-Anal 2022; 10(3): 99-121 [DOI: 10.13105/wjma.v10.i3.99] [Reference Citation Analysis]
3 Wang Y, Che Y, Wang S, Wang J, Liu X, Kou B, Guan Y, Chen D, Shi Y. ASPP2 reduction attenuates HBV induced chronic liver damage: A hybrid mouse model study. Biochemical and Biophysical Research Communications 2022;610:61-9. [DOI: 10.1016/j.bbrc.2022.03.109] [Reference Citation Analysis]
4 Zhang X, Su H, Yu H, Ding J, Deng W, Qin B, Zhou C, Dou J, Guo M. A Polysaccharide From Eupolyphaga sinensis Walker With Anti-HBV Activities In Vitro and In Vivo. Front Pharmacol 2022;13:827128. [DOI: 10.3389/fphar.2022.827128] [Reference Citation Analysis]
5 Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol 2022; 11(1): 57-72 [DOI: 10.5501/wjv.v11.i1.57] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dekker SE, Green EW, Ahn J. Treatment and Prevention of Acute Hepatitis B Virus. Clin Liver Dis 2021;25:711-24. [PMID: 34593149 DOI: 10.1016/j.cld.2021.06.002] [Reference Citation Analysis]
7 Wang Y, Wang S, Che Y, Chen D, Liu Y, Shi Y. Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics. Medicine (Baltimore) 2021;100:e26917. [PMID: 34414947 DOI: 10.1097/MD.0000000000026917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
9 Souan L, Siag M, Al-Salahat H, Al-Atrash T, Sughayer MA. Changing trends in seroprevalence rates of transfusion-transmitted diseases among blood donors in Jordan. BMC Infect Dis 2021;21:508. [PMID: 34059011 DOI: 10.1186/s12879-021-06196-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Souan L, Siag M, Al-Salahat H, Al-Atrash T, Sughayer MA. Changing trends in seroprevalence rates of transfusion-transmitted diseases among blood donors in Jordan. BMC Infect Dis 2021;21:508. [PMID: 34059011 DOI: 10.1186/s12879-021-06196-3] [Reference Citation Analysis]
11 Higashi-Kuwata N, Hayashi S, Kumamoto H, Ogata-Aoki H, Das D, Venzon D, Hattori SI, Bulut H, Hashimoto M, Otagiri M, Takamune N, Kishimoto N, Davis DA, Misumi S, Kakuni M, Tanaka Y, Mitsuya H. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. J Hepatol 2021;74:1075-86. [PMID: 33333207 DOI: 10.1016/j.jhep.2020.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Khadka S, Pandit R, Dhital S, Baniya JB, Tiwari S, Shrestha B, Pandit S, Sato F, Fujita M, Sharma M, Tsunoda I, Mishra SK. Evaluation of Five International HBV Treatment Guidelines: Recommendation for Resource-Limited Developing Countries Based on the National Study in Nepal. Pathophysiology 2020;27:3-13. [PMID: 34321716 DOI: 10.3390/pathophysiology27010002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Li MH, Chen QQ, Zhang L, Lu HH, Sun FF, Zeng Z, Lu Y, Yi W, Xie Y. Association of cytokines with hepatitis B virus and its antigen. J Med Virol 2020. [PMID: 32662892 DOI: 10.1002/jmv.26301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Zhang RX, Zhao X, Chen ST, Liu S, Li GH, Cao ZM, Xu L, Chen J. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial. Trials 2020;21:482. [PMID: 32503608 DOI: 10.1186/s13063-020-04395-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Li S, Luo S, Lei Q, Meng Z. Hepatitis B Surface Antigen Seroconversion by Interferon-α2b Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Hepatitis B Vaccine: A Case Report. Viral Immunol 2020;33:122-5. [PMID: 31880508 DOI: 10.1089/vim.2019.0119] [Reference Citation Analysis]
17 Chen MB, Wang H, Zheng QH, Zheng XW, Fan JN, Ding YL, Niu JL. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis. PLoS One 2019;14:e0224773. [PMID: 31751366 DOI: 10.1371/journal.pone.0224773] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
18 Chen MB, Wang H, Zheng QH, Zheng XW, Fan JN, Ding YL, Yue MX. Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e16943. [PMID: 31441888 DOI: 10.1097/MD.0000000000016943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]